食管钡餐连续摄影用于诊断早期食管癌的初步临床应用

目的 :介绍食管钡餐连续摄影用于诊断早期食管癌的初步临床应用。方法 :用德国产的数字化胃肠机检查并诊断了 6例早期食管癌病人。与常规食管双重对比造影类似 ,病人立位口服钡剂 ,同时进行连续摄影 ,速度为 2帧 s,持续约 10s。观察不同的时相 ,包括充盈相、黏膜相和双对比相。结果 :在 6例病人中可见食管功能的改变及黏膜皱襞的病变 ,用连续摄影诊断后经内镜及病理检查确诊。 4例病人有轻度扩张受限 ,2例病人有痉挛性收缩 ,1例有钡剂滞留。 6例病人中均可见增粗的或中断的黏膜。 5例病人可见小溃疡。结论 :食管钡餐连续摄影可提供更全面的信息。用此法更可提供食管功能性的改变。     

子宫内膜增生性病变与子宫内膜癌的超声诊断价值

目的:探讨子宫内膜增生性病变与子宫内膜癌的超声鉴别诊断及内膜癌肌浸程度的估价.方法:采用术前B超、术后大体标本观察测量,对123例子宫内膜病变患者的声像图资料进行分析并与手术后病理结果对照.结果:①子宫内膜病变者子宫三径之和平均值均大于正常值;②58.6%的子宫内膜增生过长病变患者内膜形态以条形、梭形和正常形态回声;35%的Ⅱ期以上子宫内膜癌患者内膜回声以积液为主兼有其它图像类型;③大于50岁患者不同病理类型病变的子宫内膜平均厚度均超过其正常内膜厚度值,但无明显的规律性.小于50岁的患者内膜增厚主要以子宫内膜增生过长病变为主占48%;④通过超声测量子宫内膜厚度判断子宫内膜癌浅肌层和深肌层浸润符合率均为71.4%.结论:超声检查对判断子宫内膜病变病理类型有一定帮助,内膜厚度、内膜形态、回声特点、及内膜与肌层间的关系等,仅提示病变存在的可能性,要鉴别病变的良恶性、肌层浸润深度,须根据上述回声特点进行综合分析.     

病人自控硬膜外镇痛用于肺癌术后的临床观察

目的 观察PCEA用于肺癌术后的镇痛效果。方法 60例肺癌术后患随机等分为两组：A组采用PCEA，B组肌注镇痛剂。定时监测两组MAP、HR、SpO2、VAS评分、镇静评分及不良反应等。结果 A组镇痛确切，呼吸、循环平稳，患平静合作休息好。结论 PCEA用于肺癌术后镇痛效果好，不良反应少，患满意度高。     

药物敏感试验指导肺癌合并恶性胸腔积液的顺铂联合其他药物胸腔内化疗

目的用药物敏感试验预测肺癌合并恶性胸腔积液癌细胞对顺铂联合其他药物的敏感度，观察其在指导此类患者的顺铂联合其他化疗药物胸腔内化疗的价值。方法将44例胸腔积液癌细胞阳性肺癌患者随机分为两组：药物敏感试验组（20例，有2例因体外药物敏感试验失败而被排除）和对照组（22例）。药物敏感试验组患者用三磷酸腺苷-肿瘤细胞药物敏感试验（ATP-TCA）法分别检测胸腔积液癌细胞对顺铂加香菇多糖、顺铂加甘露聚糖肽、顺铂加A群链球菌制剂、顺铂加干扰素、顺铂加金黄色葡萄球菌滤液制剂、顺铂加卡介苗多糖核酸、顺铂加红色诺卡菌细胞壁骨架、顺铂加白细胞介素-2的敏感度，并选择抑瘤率最高的联合化疗药物对患者进行胸腔内化疗，观察治疗后胸腔积液完全缓解率及胸腔积液癌细胞转阴率，并与对照组比较。结果药物敏感试验组患者对各联合化疗药物敏感的例数为：顺铂加香菇多糖14例、顺铂加甘露聚糖肽18例、顺铂加A群链球菌制剂17例、顺铂加干扰素10例、顺铂加金黄色葡萄球菌滤液制剂16例、顺铂加卡介苗多糖核酸15例、顺铂加红色诺卡菌细胞壁骨架17例、顺铂加白细胞介素-216例。药物敏感试验组完全缓解率为65．0％，对照组为27．3％（P〈0．05）。药物敏感试验组胸腔积液癌细胞转阴率为80．0％，对照组为45．5％（P〈0．05）。结论用药物敏感试验指导肺癌合并恶性胸腔积液的胸腔内个体化化疗可提高完全缓解率和胸腔积液癌细胞转阴率，该方法具有临床实用价值。     

An approach to haemorrhoids

OBJECTIVE: Many patients with haemorrhoids are investigated because of the fear of missing colorectal cancer (CRC). The aim of this study was to determine whether a primarily clinical approach regarding the need for investigation was safe and did not miss patients with CRC. PATIENTS AND METHODS: Data was collected prospectively on 589 consecutive patients with the principle diagnosis of haemorrhoids at first clinic visit. All had clinical assessment including rigid sigmoidoscopy and were treated by phenol injection or banding. They were categorized for (1) no review unless symptoms persisted -'One Stop SOS' (2) outpatient review or (3) investigation. To check for the development of CRC they were contacted by postal questionnaire or telephone interview with a minimum of one year from diagnosis and treatment. All 589 patients were cross-referenced with the Pathology database and the Hospital Information Services System. RESULTS: Four hundred and sixty-nine (80%) answered the questionnaire; 352 patients (60% of the total group) fell in the 'one stop SOS' outpatient category; 95 (16%) patients were followed up to review response to treatment for large haemorrhoids; 105 (18%) were investigated with barium enema (12%), flexible sigmoidoscopy (4%), colonoscopy (1%) and miscellaneous (1%); 37 (6%) patients were either given a haemorrhoidectomy date or referred on with a different diagnosis. No patients selected for 'one-stop' treatment developed CRC. Five (0.8%) patients were diagnosed with CRC after appropriate investigation was instituted for suspicious symptoms. One patient with distal transverse colon cancer had a delayed diagnosis as she was investigated initially by flexible sigmoidoscopy. CONCLUSION: Most patients with the primary diagnosis of symptomatic haemorrhoids do not need investigation.     

Endocrine therapy with or without radical prostatectomy for T1b-T3N0M0 prostate cancer

BACKGROUND: We retrospectively compared the 5-year survival rates of T1b-T3N0M0 prostate cancer patients treated either by endocrine therapy plus radical prostatectomy or endocrine therapy alone. METHODS: Clinical T1b-T3N0M0 prostate cancer patients were enrolled at 104 institutions in Japan. They were assigned to study 1 (n = 176), if they were indicated to prostatectomy, if not indicated, they were assigned to study 2 (n = 151). The indication of prostatectomy was based on the clinical judgement of physicians and/or patients. Those assigned to study 1 underwent prostatectomy and adjuvant endocrine therapy with or without preoperative androgen deprivation. Those assigned to study 2 were treated with leuprorelin acetate with or without chlormadinone acetate. They were followed-up every 3 months until death or for 5 years and over. RESULTS: Those assigned to study 1 were younger (mean age 67.2 vs 75.7 years), less advanced in clinical stage, and had lower prostate specific antigen levels (mean 43.8 vs 103.6 ng/mL). Death for any reason was observed less frequently in study 1 (n = 29, 16%) than study 2 (n = 50, 33%), and the 5-year overall survival rate was higher in study 1 (87 vs. 68%). However, prostate cancer deaths were comparatively seldom (9% in study 1 and 7% in study 2), resulting in the identical 5-year cause specific survival rate in both study groups (91%). In both study groups the overall survival was almost equal to the natural survival of age-matched men. CONCLUSIONS: Endocrine therapy offers a reasonable survival rate in T1b-T3 prostate cancer patients within a 5-year follow-up. Observation will be extended to determine 10-year outcomes.     

OK-432增强人腹腔抗癌免疫功能的研究

目的　探讨腹腔内注射OK - 4 32增强腹腔免疫功能的机制。方法　选择非炎症和非肿瘤手术患者作为实验对象 ,实验组分别于手术前 72小时、4 8小时和 2 4小时腹腔内注射 4KE的OK - 4 32。开腹后采集腹腔内巨噬细胞 ,并用人胃癌MKN1细胞作为靶细胞对巨噬细胞的癌细胞毒性进行分析。同时采集大网膜 ,对大网膜乳斑的数量和面积进行了观察分析。结果　OK - 4 32显著增加了腹腔内巨噬细胞的数量 (P <0 .0 5 )、增强了巨噬细胞的吞噬活性和酶活性 (P <0 .0 5 )、增加了NO的分泌和巨噬细胞的癌细胞毒性 (P <0 .0 5 ) ,以及大网膜乳斑的数量和面积 (P <0 .0 5 )。结论　手术前腹腔内注射OK - 4 32可以作为预防癌细胞腹腔内种植转移的有效方法。     

逆转录-聚合酶链反应检测胃癌淋巴结微转移

目的 检测胃癌常规病理检查阴性的淋巴结微转移的发生及与其它临床参考指标的关系。方法 利用逆转录－聚合酶链反应（RT－PCR）方法检测68枚胃癌胃周淋巴结癌胚抗原（CEA）mRNA基因表达，同时比较RT－PCR与免疫组化（IHC）方法的检测敏感性。结果 CEAmRNA RT－PCR是一种很敏感的方法，可以检测1／10^6个转移的癌细胞；检测19例胃癌患者取材的68枚胃周淋巴结，IHC阳性率28％（19／68），RT－PCR阳性率57％（39－68），两组之间差异有非常显著性意义（P＜0.01）；RT－PCR阳性率与胃部临床参考指标密切相关，且随着病期进展而增大。结论 CEA mRNA RT-PCR是比免疫组化更敏感的方法，可以预测胃癌淋巴结微转移，能够有效地避免已有微小转移的患者被漏诊。     

放疗化疗联合治疗局部晚期非小细胞肺癌43例

目的 探讨以顺铂为主的化疗方案加放疗对局部晚期非小细胞肺癌的疗效。方法 86例局部晚期非小细胞肺癌患随机分为治疗组及对照组各43例，放疗方案以CAP、EP、MVP或MOP，每人至少化疗两个周期，化疗后10～14天放射治疗，放疗采用^60Co外照射。结果 治疗组有效率83．7％，中位生存期14．5个月，对照组有效率67．4％，中位生存期10个月，两组不良反应为骨髓抑制、胃肠道反应。结论 以顺铂为主的化疗方案加放疗治疗局部晚期非小细胞肺癌的疗效较高，可提高肿瘤的局部控制率和延长生存期。